Updated guidelines for predictive biomarker testing in advanced non‑small‑cell lung cancer:: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

• P. Garrido ^[1] ; E. Conde ^[2] ; J. de Castro ^[3] ; J. J. Gómez Román ^[4] ; E. Felip ^[5] ; L. Pijuan ^[6] ; D. Isla ^[7] ; J. Sanz ^[8] ; L. Paz Ares ^[9] ; F. López Ríos ^[2]
  1. [1] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  2. [2] Hospital Universitario HM Sanchinarro

     Hospital Universitario HM Sanchinarro

     Madrid, España

     
  3. [3] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  4. [4] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  5. [5] Hospital Vall d'Hebron

     Hospital Vall d'Hebron

     Barcelona, España

     
  6. [6] Hospital del Mar

     Hospital del Mar

     Barcelona, España

     
  7. [7] Hospital Clínico Universitario Lozano Blesa

     Hospital Clínico Universitario Lozano Blesa

     Zaragoza, España

     
  8. [8] Instituto de Investigación Sanitaria del Hospital Clínico San Carlos

     Instituto de Investigación Sanitaria del Hospital Clínico San Carlos

     Madrid, España

     
  9. [9] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 7, 2020, págs. 989-1003
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • In 2011 the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) started a joint project to establish guidelines on biomarker testing in patients with advanced non-small-cell lung cancer (NSCLC) based on current evidence. As this field is constantly evolving, these guidelines have been updated, previously in 2012 and 2015 and now in 2019. Current evidence suggests that the mandatory tests to conduct in all patients with advanced NSCLC are for EGFR and BRAF mutations, ALK and ROS1 rearrangements and PD-L1 expression. The growing need to study other emerg-ing biomarkers has promoted the routine use of massive sequencing (next-generation sequencing, NGS). The coordination of every professional involved and the prioritisation of the most suitable tests and technologies for each case remains a challenge